Opposite outcomes meet at Peptide Broker
Less weight loss can be a useful result. So can more. The interesting question is who needed which outcome, and what came with it.
Weight loss in a ferret experiment
In a 2024 experiment in ferrets given cisplatin, ipamorelin reduced chemotherapy-associated weight loss. It left vomiting unchanged. That pairing is a wonderfully awkward introduction to a peptide usually discussed around sleep, recovery and physique.
Before the ferret paper, I associated peptide weight claims with a downward curve. Here, preserving weight was the aim. In tirzepatide’s obesity trial in adults without diabetes, the desired direction was down. Different species, different conditions, different purposes: these results cannot be exchanged for one another, even though both molecules circulate under the roomy heading peptides.
The ferret finding also separates two outcomes that might have seemed inseparable. Less weight loss arrived without an anti-vomiting effect. A useful change in one measurement left another problem standing. That is where the apparently simple word benefit starts to get interesting.
Four different aims
Ipamorelin: a growth-hormone pulse is measurable in healthy male volunteers. The larger question of helping people recover after bowel surgery had a less satisfying answer: its published Phase 2 trial missed the primary endpoint. Follow the meal-recovery trial.
GHK-Cu: skin repair has a persuasive biological vocabulary: collagen, copper and the cells that rebuild tissue. Yet a frequently cited hair-growth trial tested GHK in a combination formulation. I dispute GHK’s exclusive billing for a result its trial never isolated. Read about skin, copper and delivery.
PT-141: the human trials measured desire and the distress associated with low desire. Those aims deserve their own terms, alongside the nausea and other burdens of treatment. Explore bremelanotide’s outcomes.
Tirzepatide: the substantial weight changes in the obesity trials come with questions about tolerability and the consequences of continued treatment. The scale supplies an important answer; it leaves plenty to discuss. Read the tirzepatide record.
Approval and access
Bremelanotide has a U.S. prescription approval for acquired, generalised hypoactive sexual desire disorder in premenopausal women. Research-chemical PT-141 sits outside that approval. Tirzepatide is an approved prescription medicine for type 2 diabetes, chronic weight management and moderate-to-severe obstructive sleep apnoea in adults with obesity; its clinical reference chapter describes the diabetes approval and mechanism.
Topical Copper Tripeptide-1 is a legal cosmetic ingredient in the United States, European Union and United Kingdom. Injectable or oral GHK-Cu is unapproved. Ipamorelin has never been approved as a drug in any jurisdiction; the ipamorelin page sets out its compounding status and sport prohibition.
Their incompatible purposes make any overall winner look arbitrary to me. Each result has someone’s particular difficulty behind it. The comparison puts those purposes side by side, and the questions page deals with the names that tend to get tangled together.